Copyright
©The Author(s) 2016.
World J Obstet Gynecol. May 10, 2016; 5(2): 187-196
Published online May 10, 2016. doi: 10.5317/wjog.v5.i2.187
Published online May 10, 2016. doi: 10.5317/wjog.v5.i2.187
Figure 1 Surgical standard of care (n = 4434) and adjuvant chemotherapy standard of care (n = 2595) receipt by physician specialty and International Federation of Gynecologists and Obstetricians stage.
(1) Surgery SOC treatment was based on ovarian cancer patients receiving surgery prior to chemotherapy (n = 6714); (2) Stages 1, not otherwise specified and Unknown/unstaged were removed from analysis; (3) Surgeon specialty and chemotherapy specialty was categorized according to the most specialized care received during the course of the treatment window; (4) Women who received surgery SOC by a surgeon specialty who could not be identified are not shown (n = 17); (5) There were 177 women who received a chemotherapy procedure code of interest but for whom physician specialty could not be identified and 1238 women who did not receive a chemotherapy procedure code of interest. 1Denote that the estimate is statistically significantly higher for GO compared to Non-GO. SOC: Standard of care; GO: Gynecologic oncologist.
Figure 2 Ovarian cancer survivor curves1 by receipt of overall standard of care2 (n = 1678).
1All covariates held at the reference level noted in Table 3; 20 = Did not receive overall standard of care; 1 = Did receive overall SOC. SOC: Standard of care.
- Citation: Rim SH, Hirsch S, Thomas CC, Brewster WR, Cooney D, Thompson TD, Stewart SL. Gynecologic oncologists involvement on ovarian cancer standard of care receipt and survival. World J Obstet Gynecol 2016; 5(2): 187-196
- URL: https://www.wjgnet.com/2218-6220/full/v5/i2/187.htm
- DOI: https://dx.doi.org/10.5317/wjog.v5.i2.187